...
首页> 外文期刊>Vaccine >Identification of two novel immunodominant UreB CD4(+) T cell epitopes in Helicobacter pylori infected subjects
【24h】

Identification of two novel immunodominant UreB CD4(+) T cell epitopes in Helicobacter pylori infected subjects

机译:幽门螺杆菌感染受试者中的两个新型免疫优势UreB CD4(+)T细胞表位的鉴定

获取原文
获取原文并翻译 | 示例

摘要

An epitope-based vaccine is a promising option for treating Helicobacter pylori (H. pylori) infection. Epitope mapping is the first step in designing an epitope-based vaccine. A pivotal role of CD4(+) T cells in protection against H. pylori has been accepted, but few Th epitopes have been identified. In this study, two novel UreB CD4(+) T cell epitopes were identified using PBMCs obtained from two H. pylori infected subjects. We determined the restriction molecules by antibody blocking and used various Epstein-Barr virus-transformed B lymphocyte cell lines (BLCLs) with different HLA alleles as APCs to present peptides to CD4(+) T cells. These epitopes were DRB1*1404-restricted UreB(373-385) and DRB1*0803-restricted UreB(438-452). The T cells specific to these epitopes not only recognized autologous DCs loaded with recombinant UreB but also those pulsed with H. pylori whole cell lysates, suggesting that these epitope peptides are naturally processed. These epitopes have important value for designing an effective H. pylori vaccine
机译:基于表位的疫苗是治疗幽门螺杆菌(H. pylori)感染的有前途的选择。表位作图是设计基于表位的疫苗的第一步。已经接受了CD4(+)T细胞在预防幽门螺杆菌中的关键作用,但已鉴定出少量Th表位。在这项研究中,使用从两个幽门螺杆菌感染的受试者获得的PBMC鉴定了两个新的UreB CD4(+)T细胞表位。我们通过抗体阻断来确定限制性分子,并使用具有不同HLA等位基因的各种爱泼斯坦-巴尔病毒转化的B淋巴细胞细胞系(BLCL)作为APC,以向CD4(+)T细胞呈递肽。这些表位是DRB1 * 1404限制的UreB(373-385)和DRB1 * 0803限制的UreB(438-452)。特异于这些表位的T细胞不仅识别装载重组UreB的自体DC,而且识别被幽门螺杆菌全细胞裂解物脉冲的TDC,这表明这些表位肽是天然加工的。这些表位对于设计有效的幽门螺杆菌疫苗具有重要价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号